Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-07

Clinical Trial Update: Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) [Phase 2]

View source ↗

Summary

Phase 2B study of ataluren (PTC124) in Duchenne/Becker muscular dystrophy completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2020-04-07